Detail akcie Gilead Sciences online

Business Summary: Gilead Sciences, Inc. is a biopharmaceutical company. The Company is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis, COVID-19, cancer and inflammation. It is focused on discovering, developing and delivering medicines to address unmet medical needs in virology, oncology and other therapeutic areas. Its portfolio of marketed products includes Biktarvy, Genvoya, Descovy, Complera/Eviplera, Symtuza, Truvada, Stribild, Sunlenca, Epclusa, Vemlidy, Harvoni, Viread, Livdelzi, Veklury, Yescarta, Tecartus, Trodelvy, AmBisome, and Letairis. Its product candidates include Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, Anitocabtagene autoleucel, Sacituzumab govitecan-hziy, and Domvanalimab and zimberelimab. Biktarvy is an oral formulation dosed once a day for the treatment of HIV-1 infection in certain patients. It operates in more than 35 countries worldwide.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2024, Gilead Sciences Inc revenues increased 6% to $28.75B. Net income applicable to common stockholders decreased 92% to $480M. Revenues reflect United States segment increase of less than 1% to $19.51B, Europe segment increase of 1% to $4.35B. Net income was offset by discovery, development and commercialization of innovative m segment income decrease of 78% to $1.66B.